As a result of studies of the biochemical mechanisms of aminoglycoside resistance, new semisynthetic aminoglycoside antibiotics, i.e., 3',4'-dideoxykanamycin B (DKB) (11) , amikacin (AK) (5) and 6'-N-methyl DKB (6'-Me-DKB) (13) , were prepared and found to be effective against various species of bacterial strains (including Pseudomonas aeruginosa) resistant to the known aminoglycoside antibiotics. Recently, we have isolated P. aeruginosa strains resistant to DKB and AK, which inactivate the drugs by an aminoglycoside 6'-N-acetyltransferase activity, as already reported in Escherichia coli (1, 9, 10) and P. aeruginosa (2, 4, 6, 8, 12, 14) . Further studies have disclosed that almost all strains of P. aeruginosa resistant to both DKB and AK are susceptible to 6'-Me-DKB. Recently, we have isolated two P. aeruginosa strains, i.e., GN4925 and GM5462, resistant to DKB and 6'-Me-DKB, but susceptible to AK. This paper deals with their biochemical mechanism of resistance to DKB and 6'-Me-DKB, and a comparison with that of the (DKB.AK) resistance.
MATERIALS AND METHODS
Bacterial strains. P. aeruginosa strains were isolated from clinical specimens and stocked in this laboratory. Their resistance patterns to kanamycin A (KM-A), DKB, gentamicin C complex (GM), 6'-Me-DKB, streptomycin (SM) and AK are shown in Table TABLE 1 a Two strains of P. aeruginosa were used as recipients in R factor transfer.
used for liquid culture. Minimal medium was used for the transfer of the R factor from exconjugant ML4561 to ML4344.
Determination of drug resistance. One loopful of a 100-fold dilution (about 106 cells/ml) of an overnight broth culture was spotted on heart infusion agar (Eiken, Tokyo) plates containing serial twofold dilutions of each antibiotic. The minimal inhibitory concentration of each drug was scored after 18 h of incubation at 37 C.
Preparation of the S-105 fraction and inactivation reaction. The S-105 fraction from P. aeruginosa was prepared by a procedure described previously (2) . The reaction mixture consisted of 0. in a total volume of 192 ml. The reaction mixture was diluted with 300 ml of distilled water and the reaction was stopped by heating at 100 C for 10 min. The supernatant fluid obtained by centrifugation at 30,000 x g for 30 min was passed through a column of Amberlite CG-50 (NH4+ form, 50 ml), and the column was washed with 2,000 ml of distilled water. The inactivated DKB was then eluted with 0.1 N NH4OH. The eluate fractions which gave a positive ninhydrin reaction were collected and concentrated to dryness. The powder was applied to a thin-layer chromatogram. After chromatography the spot was raked up, washed with distilled water, and then extracted with 0.3 N NH4OH and dried. This powder was further subjected to chromatography on Amberlite CG-50-(NH4+ form, 20 ml).
Thin-layer chromatography. Thin-layer chromatography was carried out using the following solvent system on a thin layer of silica gel (Tokyo Kasei Co., Tokyo): buthanol-ethanol-CHCls-17% NH4OH (4:5:2:5). The spot on a chromatogram was detected by the ninhydrin reaction.
Conjugal transfer of resistance. From each donor and recipient culture in nutrient broth at 37 C for 18 h, 0.5 ml was removed and inoculated into 5 ml of fresh nutrient broth and shaken at 37 C. After 2 h of incubation, the cultures (about 2 x 109 cells/ml) reached the late logarithmic phase of growth and were used for the conjugal transfer of resistance. One part of donor culture was mixed with four parts of recipient culture and the mixture was incubated at 37 C with gentle shaking. After 90 min of incubation, a 0.1-ml sample of the mixed culture was plated on selective plates containing rifampin (200 Ag/ml) and either DKB (3.1 ug/ml) or GM (3.1 ug/ml). The colonies which developed on selective plates after 18 h of incubation af 37 C were picked and purified by three successive single cQlony isolations, and their drug resistance was then determined. For the transfer of resistance from exconjugant ML4561 to ML4344, the minimal medium containing DKB (or GM), leucine (50 ,ug/ml), and tryptophan (50 Mg/ ml) was used for the selection of exconjugant ML-4344. The transfer frequency was expressed as the ratio of the number of donor to recipient cells which acquired drug resistance by conjugation.
Partial purification of the inactivating enzyme. Aminoglycoside acetyltransferase was purified by affinity chromatography. KM A-Sepharose 4B was prepared as follows: cyanogen bromide-activated Sepharose 4B (Pharmasia Fine Chemicals AFB, Upsala, Sweden) was washed with 1,000 ml of 1 mM HCl, 500 ml of cold water, and 25 ml of 0.1 mM NaHCO,-0.5 M NaCl, successively, and was mixed with 0.5 g of KM in 45 ml of 0.1 M NaHCO3-0.5 M NaCl. The mixture was stirred at 4 C for 24 h. KM A-Sepharose 4B thus prepared was washed several times with 50 ml of 0.1 M acetate buffer-1.0 M NaCl (pH 4.0), and then with 50 ml of 0.1 M borate buffer-1.0 M NaCl (pH 8.0), alternately. Then the KM A-Sepharose 4B was washed with distilled water and with 20 mM acetate buffer (pH 6.0)-20% glycerin, containing 5 that almost all strains of P. aeruginosa were susceptible to the newly introduced antibiotics: DKB, AK, and 6'-Me-DKB. It should be noted however, that a few DKB-resistant P. aeruginosa strains existed in our stock cultures, even before the widespread clinical use of the drug. Most of the DKB-resistant P. aerugirnosa strains were still susceptible to AK and 6'-Me-DKB. Similarily, we could isolate DKB, AKresistant strains of P. aeruginosa which were susceptible to 6'-Me-DKB. Recently, we have isolated from clinical specimens two P. aeruginosa strains resistant to DKB and 6'-Me-DKB but susceptible to AK. The minimal inhibitory concentration levels of various aminoglycoside antibiotics toward representative strains from our stock cultures are shown in Table 1 .
Inactivation of aminoglycoside antibiotics. We prepared the S-105 fractions from strains GN4925, GN315, ML4344, and from the ML4344 strains which had acquired resistance by conjugation with strains GN4925 and GN315, respectively, and investigated the biochemical mechanisms of resistance to aminoglycoside antibiotics. Inactivation reaction did not take place without either CoA or ATP. However ATP, CoA, and magnesium acetate could be replaced by acetyl CoA. The inactivation of DKB, 6'-Me-DKB and AK by extracts of these strains is summarized in Table 2 . Extracts from strain GN4925 that is resistant to DKB and 6'-Me-DKB, but susceptible to AK, inactivated both DKB and 6'-Me-DKB, but not AK. By contrast, extracts of strain GN315 inactivated both DKB and AK, but not 6'-Me-DKB. Since the inactivation reaction requires the presence of acetyl CoA, the inactivation was considered to be due to acetylation of the drugs. We next investigated the incorporation of
[I4C ]acetate into various aminoglycoside antibiotics by the inactivation reaction using extracts of strain GN4925 (Table 3) .
As shown in Table 3 , the rate of inactivation almost paralleled the rate of incorporation of
[14C ]acetate. From these results, we conclude that strain GN4925 inactivated aminoglycoside antibiotics by acetylation. Strain GN4925 was resistant to the GM-C complex including GM-C1, but could not inactivate GM-Cl under the conditions used. The mechanism of this GM resistance will be described elsewhere.
Conjugal transfer of resistance. Conjugal transferability of resistance in strain GN4925 and GN5462 was examined using strain ML4561 and ML4344 as a recipient. Strain GN4925 could transfer its resistance to KM, DKB, GM, SM, and SA, including 6'-Me-DKB and 6'-Me-KM. An exconjugant, strain ML4561, which had acquired these resistances, could conjugally transfer the same resistance pattern as strain GN4925. Similarly, strain GN5462 could transfer resistance to KM, DKB, TC, CM, SM, and SA. These results indicate that the genes governing resistance to these drugs were located on R plasmids, henceforth called Rms167 and R,x,,168, respectively. Typical results are shown in Table   4 .
Purification of inactivating enzyme. The S-105 fraction from GN4925 was passed through a KM A-Sepharose 4B column and eluted by linear gradient elution with NaCl from 0 to 0.7 M in 20 mM acetate buffer (pH 6.0)-20% glycerin containing 5 mM magnesium acetate and 10 mM 2-mercaptoethanol. The enzyme which inactivated KM, DKB, and 6'-Me-DKB appeared in the elutate at 0.45 M NaCl and inactivation curves of both DKB and 6'-Me-DKB using eluted fractions were almost the same. The DKB-and 6'-Me-DKB-inactivating enzyme was purified approximately 96-fold from the S-105 fraction in this way. The optimal pH for DKB and 6'-Me-DKB inactivation was about 6.0, and the pH curves for inactivation of two drugs and time course of inactivation of both were almost identical. The results are shown in Fig. 1 and 2 . These results indicated that an aminoglycoside acetyltransferase from strain GN4925 could inactivate KM, DKB, and 6'-Me-DKB.
Identification of the acetylated product.
DKB inactivated by extracts of GN4925 was purified and obtained as a white powder. The nuclear magnetic resonance spectra of the inactivated DKB and a synthetic sample of 6'-Nacetyl DKB were found to be similar to each other (Fig. 3) . In the nuclear magnetic resonance spectrum of the inactivated DKB in D,O (16.4 mg/0.25 ml), using tetramethylsilane as the external reference, one N-acetyl signal was seen at a 2.34. Application of the double resonance technique indicated that the signal of the C-6' methylene protons at 6 3.15 in DKB shifted to a 3.7 in the acetylated DKB. This structure was also consistent with its mass spectrum: a peak of a mono-N-acetyl DKB at m/e 494(M + 1) and an intense peak at m/e 171 attributed to the N-acetyl-3',4'-dideoxyneosamine C unit (Fig. 4) . Thus, the structure of the inactivated DKB was determined to be 6'-N-acetyl DKB. amino group of the deoxystreptamine moiety in KM-A could protect AK from acetylation by the enzyme AAC(6')-3. This fact suggests the disturbance of the formation of enzyme-substrate complex by 1-N-acylation of KM-A. The finding that enzymes capable of acetylating the 6' of aminoglycoside antibiotics can be divided into two groups depending on whether they are capable of inactivation of 6'-N-methyl aminoglycoside antibiotics and AK or not will be useful in studies of the chemical modification of aminoglycoside antibiotics. specimens. The inactivation enzymes are known to be aminoglycoside phosphotransferase, aminoglycoside adenylytransferase, and aminoglycoside acetyltransferase. Aminoglycoside 6'-N-acetyltransferase, i.e., AAC(6'), has been further classified into subgroups owing to its substrate profiles and susceptibility to the drugs, namely AAC(6')-1, -2, -3, and -4 (7). The enzyme AAC(6')-1 acetylate KM-A, KM-B, and neomycin (NM), but not other aminoglycoside antibiotics such as GM, DKB, and AK. The enzyme AAC(6')-2 inactivates KM-A, KM-B, NM, GM-Cia, and GM-C2, but not DKB and AK. The enzyme AAC(6')-3, described in the present article, which acetylates KM-A, KM-B, NM, Gm-Cia, GM-C2, and DKB, but cannot acetylate AK GM-C2, was a poor substrate. The enzyme AAC(6')-4 acetylates KM-A, KM-B, GM-Cia, GM-C2, DKB, and AK (4, 6). There are thus two types of enzymes capable of acetylating DKB, i.e., AAC(6')-3 and AAC(6')-4. One is capable of acetylating both DKB and AK, but not 6'-Me-DKB. The enzyme AAC(6')-3 can acetylate the 6' amino groups except that of AK, and can acetylate the 6' secondary amine of aminoglycosides, i.e., 6'-Me-KM and 6'-Me-DKB. Acylation of the one 
